mouse anti glial fibrillary acidic protein gfap (Cell Signaling Technology Inc)
94
Structured Review
Cell Signaling Technology Inc
mouse anti glial fibrillary acidic protein gfap
Mouse Anti Glial Fibrillary Acidic Protein Gfap, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 26 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+gfap/EAAT2+Rabbit+mAb/pm42863728-141-35-42
Average 94 stars, based on 26 article reviews
Mouse Anti Glial Fibrillary Acidic Protein Gfap, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 26 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+gfap/EAAT2+Rabbit+mAb/pm42863728-141-35-42
Average 94 stars, based on 26 article reviews
mouse anti glial fibrillary acidic protein gfap - by Bioz Stars,
2026-11
94/100 stars
Images
Related Articles
Incubation:Article Title: GABA-Induced Exosomes Improve Memory Impairment in Aged Mice Article Snippet: After washing with 0.1% Tween 20/TBS, the tissues were blocked with Blocking One Histo (Nacalai Tesque) for 1 h at 25 °C. .. Brain sections were incubated with primary antibodies for anti-Iba1 (#17197, Cell Signaling Technology, Danvers, MA, USA), Article Title: GABA-Induced Exosomes Improve Memory Impairment in Aged Mice. Article Snippet: After washing with 0.1% Tween 20/TBS, the tissues were blocked with Blocking One Histo (Nacalai Tesque) for 1 h at 25 ◦C. .. Brain sections were incubated with primary antibodies for anti-Iba1 (#17197, Cell Signaling Technology, Danvers, MA, USA), Article Title: B4Galnt1 Deficiency Reverses Severe Neurological Symptoms in a Mouse Model of Tay-Sachs Disease. Article Snippet: .. Primary antibodies— anti-GM2 (1:200; KM966), Article Title: β-Adducin Restrains PLA2G4A-Dependent Lysosomal Membrane Permeabilization and Neuronal Death in Ischemic Stroke. Article Snippet: .. Subsequently, they were incubated overnight t 4◦C with the following primary antibodies: anti- β-adducin 1: 200, Origene, #AP20545PU-N), anti-Iba1 (1: 500, Abcam, ab5076), Article Title: B4Galnt1 Deficiency Reverses Severe Neurological Symptoms in a Mouse Model of Tay-Sachs Disease Article Snippet: .. Primary antibodies—anti-GM2 (1:200; KM966), Article Title: An acyclic nucleic acid-modified siRNA targeting CAG expansions for polyglutamine disease treatment Article Snippet: We separated equal amounts of the protein on 5%–20% or 15% SDS-PAGE gels (Wako, Osaka, Japan) and transferred them to Hybond-P membranes (GE Healthcare, Piscataway, NJ). .. The membranes were incubated with the following primary antibodies: anti-AR (1:2,000; D6F11, Cell Signaling Technology, Beverly, MA), anti-GAPDH (1:5,000; Loading control, Abcam, Cambridge, MA), Article Title: An acyclic nucleic acid-modified siRNA targeting CAG expansions for polyglutamine disease treatment Article Snippet: .. The sections were then incubated overnight with the following primary antibodies: anti-polyQ 1C2 (1:20,000; MAB1574, Millipore, Billerica, MA), anti-ChAT (1:1,000, AB144P, Millipore), anti-ATXN3 (1:1,000, MAB5360, Sigma-Aldrich), anti-NeuN (1:100, ABN78A4A, Sigma-Aldrich), Blocking Assay:Article Title: B4Galnt1 Deficiency Reverses Severe Neurological Symptoms in a Mouse Model of Tay-Sachs Disease. Article Snippet: .. Primary antibodies— anti-GM2 (1:200; KM966), Article Title: B4Galnt1 Deficiency Reverses Severe Neurological Symptoms in a Mouse Model of Tay-Sachs Disease Article Snippet: .. Primary antibodies—anti-GM2 (1:200; KM966), Cell-Signaling:Article Title: An acyclic nucleic acid-modified siRNA targeting CAG expansions for polyglutamine disease treatment Article Snippet: We separated equal amounts of the protein on 5%–20% or 15% SDS-PAGE gels (Wako, Osaka, Japan) and transferred them to Hybond-P membranes (GE Healthcare, Piscataway, NJ). .. The membranes were incubated with the following primary antibodies: anti-AR (1:2,000; D6F11, Cell Signaling Technology, Beverly, MA), anti-GAPDH (1:5,000; Loading control, Abcam, Cambridge, MA), Article Title: An acyclic nucleic acid-modified siRNA targeting CAG expansions for polyglutamine disease treatment Article Snippet: .. The sections were then incubated overnight with the following primary antibodies: anti-polyQ 1C2 (1:20,000; MAB1574, Millipore, Billerica, MA), anti-ChAT (1:1,000, AB144P, Millipore), anti-ATXN3 (1:1,000, MAB5360, Sigma-Aldrich), anti-NeuN (1:100, ABN78A4A, Sigma-Aldrich), Control:Article Title: An acyclic nucleic acid-modified siRNA targeting CAG expansions for polyglutamine disease treatment Article Snippet: We separated equal amounts of the protein on 5%–20% or 15% SDS-PAGE gels (Wako, Osaka, Japan) and transferred them to Hybond-P membranes (GE Healthcare, Piscataway, NJ). .. The membranes were incubated with the following primary antibodies: anti-AR (1:2,000; D6F11, Cell Signaling Technology, Beverly, MA), anti-GAPDH (1:5,000; Loading control, Abcam, Cambridge, MA), Immunofluorescence:Article Title: Chloride intracellular channel 4 contributes to Aβ-induced cognitive impairment in mice through the regulation of mitochondrial fission. CLIC4 promotes mitochondrial fission. Article Snippet: Alzheimer’s disease (AD) is a prevalent neurodegenerative disorder characterized by impaired memory and cognitive decline.. The early stages of AD in mice present with neuropathy in the hippocampus.. Excessive mitochondrial fragmentation and dysfunction are critical pathological features of AD. |
